Previous reports showed that mouse vaccination with pluripotent stem cells (PSCs) induces
durable anti-tumor immune responses via T cell recognition of some elusive oncofetal …

Cancer cells and embryonic tissues share a number of cellular and molecular properties,
suggesting that induced pluripotent stem cells (iPSCs) may be harnessed to elicit anti-tumor …

Cancer is maintained by the activity of a rare population of self-renewing “cancer stem
cells”(CSCs), which are resistant to conventional therapies. CSCs over-express several …

Induced pluripotent stem cells (iPSCs) and cancer cells share cellular similarities and
transcriptomic profiles. Here, we show that an iPSC-based cancer vaccine, comprised of …

Simple Summary Effective cancer immunotherapies, with the objective to boost tumor-
specific immune responses, is a game-changer in personalized cancer treatment. In …

Introduction: Although many current cancer therapies are effective, the mortality rate globally
is unacceptably high. Cancer remains the second leading cause of death worldwide after …

Cancers frequently evade immune-recognition by lowering peptide: MHC-I complexes on
their cell surface. Limited peptide supply due to TAP-deficiency results in such MHC-Ilow …

Recent studies have suggested that the core pathways regulating pluripotency in embryonal
stem cells bear considerable overlap with oncogenesis. Here, we discuss recent insights …

Over a century ago, it was reported that immunization with embryonic/fetal tissue could lead
to the rejection of transplanted tumors in animals. Subsequent studies demonstrated that …

Avoiding the immune rejection of transplanted T cells is central to the success of allogeneic
cancer immunotherapies. One solution to protecting T-cell grafts from immune rejection …